Please use this identifier to cite or link to this item:
Title: Lychnopholide in PLA-PEG nanocapsules cures infection by drug resistant Trypanosoma cruzi strain in acute and chronic phases.
Authors: Branquinho, Renata Tupinambá
Mello, Carlos Geraldo Campos de
Oliveira, Maykon Tavares de
Reis, Levi Eduardo Soares
Vieira, Paula Melo de Abreu
Guimarães, Dênia Antunes Saúde
Mosqueira, Vanessa Carla Furtado
Lana, Marta de
Issue Date: 2020
Citation: BRANQUINHO, R. T. et al. Lychnopholide in PLA-PEG nanocapsules cures infection by drug resistant Trypanosoma cruzi strain in acute and chronic phases. Antimicrobial Agents and Chemotherapy, v. 64, p. AAC.01937-19, jan. 2020. Disponível em: <>. Acesso em: 10 fev. 2020.
Abstract: Chagas disease remains neglected, and current chemotherapeutics present severe limitations. Lychnopholide (LYC) at low doses loaded in polymeric poly(d,l-lactide)-block-polyethylene glycol (PLA-PEG) nanocapsules (LYC-PLA-PEG-NC) exhibits anti-Trypanosoma cruzi efficacy in mice infected with a partially drug-resistant strain. This study reports the efficacy of LYC-PLA-PEG-NC at higher doses in mice infected with a T. cruzi strain resistant to benznidazole (BZ) and nifurtimox (NF) treated at both the acute phase (AP) and the chronic phase (CP) of infection by the oral route. Mice infected with the T. cruzi VL-10 strain were treated by the oral route with free LYC (12 mg/kg of body weight/day), LYC-PLA-PEG-NC (8 or 12 mg/kg/day), or BZ at 100 mg/kg/day or were not treated (controls). Treatment efficacy was assessed by hemoculture (HC), PCR, enzyme-linked immunosorbent assay (ELISA), heart tissue quantitative PCR (qPCR), and histopathology. According to classical cure criteria, treatment with LYC-PLA-PEG-NC at 12 mg/kg/day cured 75% (AP) and 88% (CP) of the animals, while at a dose of 8 mg/kg/day, 43% (AP) and 43% (CP) were cured, showing dose-dependent efficacy. The negative qPCR results for heart tissue and the absence of inflammation/fibrosis agreed with the negative results obtained by HC and PCR. Thus, the mice treated with the highest dose could be considered 100% cured, in spite of a low ELISA reactivity in some animals. No cure was observed in animals treated with free LYC or BZ or the controls. These results are exceptional in terms of experimental Chagas disease chemotherapy and provide evidence of the outstanding contribution of nanotechnology in mice infected with a T. cruzi strain totally resistant to BZ and NF at both phases of infection. Therefore, LYC-PLA-PEG-NC has great potential as a new treatment for Chagas disease and deserves further investigations in clinical trials.
ISSN: 1098-6596
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
1,88 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.